期刊
BIOMOLECULES
卷 12, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/biom12081150
关键词
PA200; PSME4; proteasome
资金
- BMBF (German Ministry of Research) [16GW0287]
This article discusses the role and dysregulation of the proteasome regulator PA200 in human diseases, highlighting its potential as a therapeutic target in cancer.
Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research on this enigmatic proteasome regulator that has the potential to serve as a therapeutic target in cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据